STUDY PROTOCOL

Nurse-Led Telehealth Oncology Clinic on ‘Home Management During Chemotherapy’ for Gastrointestinal Cancer Patients: Study Protocol of a Mixed Method Study

Sarita Ahwal1*, Kanika Rai2, Ankur Jindal3, Puja Sahai4

1Chitkara School of Health Sciences, Chitkara University, Punjab; Institute of Liver and Biliary Sciences, New Delhi, India
2Centre for Evidence Based Practice in Health Care, Chitkara School of Health Sciences, Chitkara University, Punjab, India
3,4Institute of Liver and Biliary Sciences (ILBS), New Delhi, India

DOI: 10.55489/njcm.150720243991

A B S T R A C T

Introduction: Telehealth is increasingly being used for symptom management among cancer patients on chemotherapy. Objective of the study is to develop Nurse-led Tele-health Oncology Clinic for GI cancer patients regarding ‘Home Management during Chemotherapy’.

Methods: The study will follow sequential explanatory mixed method design where during quantitative phase, using RCT (CTRI/2024/01/062028), GI cancer patients of age 18-65 years and undergoing 2nd or 3rd chemotherapy cycle will be randomised after obtaining consent to experimental (EG) & control (CG) groups. Ethical Clearance is already obtained. EG will be followed through Nurse-led Clinic which includes multiple virtual educational & counselling sessions, e-booklet on side effects management, PMRT, Support groups & telephonic follow ups. Effectiveness will be measured in terms of Quality of life, severity of side effects and Anxiety using FACT-G, CTCAE and DASS respectively. In qualitative phase, using extreme case sampling, in-depth interviews from consented participants will be conducted to explore experiences towards intervention.

Analysis: Analysis of quantitative data will use descriptive and inferential statistics. This follows thematic analysis and integration of data.

Conclusion: The study protocol will provide guidance to optimize utility of tele-medicine technology to improve healthcare outcomes especially for the GI cancer patients.

Key words: Nurse-led clinic, telehealth clinic, oncology clinic, Gastrointestinal cancer patients, chemotherapy, self-management, PMRT, Quality of life, severity of side effects

A R T I C L E   I N F O

Financial Support: None declared
Conflict of Interest: None declared
Received: 29-03-2024, Accepted: 09-05-2024, Published: 01-07-2024
*Correspondence: Ms. Sarita Ahwal (Email: saritanadiya222@gmail.com)


Copy Right: The Authors retain the copyrights of this article, with first publication rights granted to Medsci Publications.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Share Alike (CC BY-SA) 4.0 License, which allows others to remix, adapt, and build upon the work commercially, as long as appropriate credit is given, and the new creations are licensed under the identical terms.

www.njcmindia.com | pISSN: 0976-3325 | eISSN: 2229-6816 | Published by Medsci Publications
INTRODUCTION

Gastrointestinal (GI) cancer cases are rising day by day representing over one-quarter (26%) of the global cancer incidence and over one-third (35%) of all cancer-related deaths. As per the global burden of cancer report across India from 1990-2016, the number of new cases and deaths due to cancer doubled in India. Gastrointestinal cancers with high incidence in India included stomach, colorectal, oesophageal, liver, gallbladder, and biliary tract cancers.

Chemotherapy is the treatment of choice for cancer patients but is associated with many side effects. The most common chemotherapy-induced side effects are nausea and vomiting, fatigue, decreased appetite, changes in taste, hair loss, dry mouth, and constipation. Other prominent ones include diarrhoea, numbness or tingling in hands and/or feet, skin changes (e.g. dry skin, redness, itch), fever, oral mucositis, flu-like symptoms, allergic reaction, memory problems, decreased kidney function, hearing loss and/or tinnitus.

The severity of such side effects may vary among patients and in some they can even become life-threatening. Cancer patients have been reported to have the side effects when they are home. In many cancer patients, the continuity of chemotherapy is negatively influenced by the side effects as they have been negatively associated with the quality of life among cancer patients. Therefore, it is essential to identify the side effects in time and provide possible management at the earliest possible.

Quality of life (QOL) is considered important determinant for making treatment related decisions. Quality of life is documented to be more adversely affected in early chemotherapy cycles (cycle 2-5) as compared to the subsequent cycles (i.e., cycle 5 to 6). Measures focusing on QoL of patient have been associated with better as well as patient outcomes and patient satisfaction.

Cancer patients have also reported stress related to the diagnosis and treatment. Chemotherapy can cause physical and mental impairment among cancer patients. A high prevalence of anxiety and depression has been documented among cancer patients undergoing chemotherapy. Anxiety can increase the severity of physical and psychological side effects and can decrease quality of life among cancer patients.

Progressive Muscle Relaxation Therapy (PMRT) has been documented to be effective in reducing anxiety among cancer patients. In addition to its effect on anxiety among cancer patients, PMRT may be beneficial to alleviate chemotherapy related side-effects as well. Studies have recommended PMRT therapy for cancer patients receiving chemotherapy to decrease chemotherapy related nausea/vomiting. However, more clinical trials need to be conducted on patients suffering with different types of cancer before PMRT is made as an integral part of the standard cancer treatment as a supportive therapy.

Various factors related to patients’ dissatisfaction have been identified such as lack of information, communication gaps, continuity of care, long waiting hours, duration of consultations, availability and accessibility of the healthcare professionals. Throughout treatment, symptom management is a crucial component of patient care. Providing access to comprehensive and timely information is key to treatment adherence among patients receiving chemotherapy. Furthermore, adequate information is helpful in reducing anxiety and improving the QoL among patients.

It has been demonstrated that nurse-led therapies greatly enhance cancer patients’ physical and mental wellbeing. The impact of multifaceted health interventions on quality of life is strengthened. Henceforth, Nurse led clinics being multidimensional in nature may prove to be an effective way to provide holistic care to the cancer patients receiving chemotherapy. Nurse-led clinics when made an integral part of patient care may prove to be cost effective model of care for cancer patients. They might be helpful in reducing the severity of chemotherapy related side effects with their easy access and availability of nursing expert for managing the cancer patients.

The utilization of telehealth has grown exponentially although more after COVID-19. However, determining if telehealth is a successful treatment strategy for cancer patients which is considered to be one among the high risk health conditions is crucial. Using telecommunication technology to deliver the care through nurse-led Tele-health oncology clinic further supports the idea to deploy digital health across the continuum of care as recommended in the national health policy 2017 of India.

The aim of the present study is to evaluate the impact of Nurse-led Telehealth Oncology Clinic on ‘Home Management during Chemotherapy’ among GI Cancer patients.

METHODOLOGY

The protocol follows Recommendations for Interventionsal Trials (SPIRIT) 2013 for study protocol. The protocol is registered under Clinical Trial Registry-India (CTRI) with registration number: CTRI/2024/01/062028.

Ethical consideration: Written informed Consent will be obtained before enrolment in the preferred language. The confidentiality will be maintained throughout the study. The study doesn’t include any risk or harm to the participants. Both the groups will continue with their standard routine care. The control group participants will also be provided the intervention on completion of data collection. Ethical permissions from both the University (EC/NEW/
Ahwal S et al.

INSTR/2023/531/188) and the data collection site (IEC/2022/97/MA02) have been obtained.

**Study design:** The study will adopt a sequential explanatory mixed method design where the study is to be conducted in two phases, quantitative followed by qualitative phase. Randomised control group design for quantitative phase and narrative analysis design for qualitative phase will be used (Figure 1).

**Study design:**

The study will adopt a sequential explanatory mixed method design where the study is to be conducted in two phases, quantitative followed by qualitative phase. Randomised control group design for quantitative phase and narrative analysis design for qualitative phase will be used (Figure 1).

**Study arms:** Experimental group will attend Nurse-led telehealth Oncology Clinic on ‘Home Management during Chemotherapy through virtual psychoeducational sessions and follow-ups. Patient in the control group will receive routine care as per the hospital protocol.

**Description of the intervention:** Intervention is designed in the form of Nurse led tele-health Oncology Clinic and has been validated by Nine experts in the field of Medical Surgical Nursing, Oncology, Psychiatry and Psychology. This comprises of a virtual clinic managed independently by the Nurse researcher using telemedicine technology to provide evidence based psychoeducational nursing intervention (Figure 2) to the GI Cancer patients receiving chemotherapy.

**Routine care:** This will include education provided by the treating physician and the Oncology Nurse re-
regarding the home management of chemotherapy related side effects in the form of verbal instructions and discharge sheet provided at the time of discharge. This doesn’t include any telephonic contacts with the patients for follow up after they get discharged. The control group will receive only the routine care whereas the experimental group will receive Oncology tele-health Clinic as intervention in addition to the routine care.

**Intervention nurses:** Principal Investigator (PI) is a Ph.D. (Nursing) Scholar and has undertaken one month training from a clinical psychologist to be a certified PMRT trainer. The PI is responsible to implement the intervention and to collect the data.

**Screening and recruitment of participants:** During the quantitative phase, using convenience sampling technique GI cancer patients will be first contacted during their visit to Oncology Day care for chemotherapy and screened for their eligibility to participate in the study based on inclusion and exclusion criteria. Participant information sheet will be discussed and written informed consents will be obtained from the study participants for their recruitment in the study and then they will be randomised to either the experimental or control groups. The consort diagram is shown in figure 3.

**Study sites:** The enrolment of the study participants will be done through Oncology Day care centre at a superspeciality hospital in New Delhi. The data collection for both the experimental and control groups will be done during their visit to Oncology Day care for chemotherapy cycles. The setting is not currently running any nurse-led clinic for cancer patients receiving chemotherapy.

**Eligibility criteria:** All gastrointestinal cancer patients receiving chemotherapy at Onco day care and fulfilling the inclusion and exclusion criteria (Table 1) are eligible to take part in the study.

**Sample size**

**Quantitative phase:** The sample size is statistically calculated using power analysis formula. Hence, assuming \( \alpha=5\% \) and power=80\% and 2 follow ups, we need to enroll 100 cases i.e. 50 in each experimental and control groups. Further, considering 10\% drop outs, 55 is the final sample to be taken in each group.

**Qualitative phase:** The number of participants to be interviewed is based on data saturation. Once data saturation is observed, 2-3 more participants will be interviewed to confirm data saturation.

**Screening and recruitment of participants:** During the quantitative phase, using convenience sampling technique GI cancer patients will be first contacted during their visit to Oncology Day care for chemotherapy and screened for their eligibility to participate in the study based on inclusion and exclusion criteria. Participant information sheet will be discussed and written informed consents will be obtained from the study participants for their recruitment in the study and then they will be randomised to either the experimental or control groups. The consort diagram is shown in figure 3.

For qualitative phase, out of the participants of quantitative phase, using convenience sampling technique, the participants from the experimental group will be enrolled for the qualitative phase of the study during their 2nd follow up for chemotherapy based on their consent to participate.

**Randomisation:** During the quantitative phase, using 1:1 permuted block computerised randomisation technique of block size six, GI cancer patients will be randomly allocated to the experimental and control groups. The experimental group will receive treatment in the form of Nurse-led Tele-health Oncology Clinic in adjunct to the routine care whereas the control group will receive standard routine care as per the hospital protocol. The patients will be followed up telephonically for two consecutive chemotherapy cycles (Figure 4). Further, blinding is not possible in this study.

**Study piloting:** The intervention and the tools were pilot tested from June-July, 2023 with 26 GI cancer patients. The study was found to be feasible to conduct.

**Data collection tools and technique:** The tools have been selected after extensive review of literature and expert’s guidance. Tools for quantitative phase comprised of a structured questionnaire, Functional Assessment of Cancer Therapy - General (FACT-G).25 Common Terminology Criteria for Adverse Events (CTCAE) Version-5.26 and Depression anxiety stress scale (DASS).27 to assess socio-clinical profile of the patient, Quality of Life, severity of
chemotherapy related side effects and Anxiety respectively. All tools used in the study are available on public domain except the Hindi version of FACT-G for which required approval and licensing has been obtained. Structured face to face individual interview technique using Google form will be used to collect and record the data.

Karnofsky Performance Status (KPS) scale developed by David A. Karnofsky in 1949 will be used to screen the patients at the time of enrolment. The KPS is an 11-point rating scale which ranges from normal functioning (100) to dead (0) in ten-point increments. A higher score means the patient is better able to carry out daily activities. In the present study, cancer patients with KPS score <30 will be excluded where a patient is Disabled, requires special care and hospitalization.

![Figure 3: CONSORT flow chart](image1)

![Figure 4: RCT with two follow ups](image2)

R: 1:1 Permutated Block randomisation  
E: Experimental group: GI cancer patients receiving 2nd or 3rd chemotherapy cycle  
C: Control group: GI cancer patients receiving 2nd or 3rd chemotherapy cycle  
O1: Pretest on the day of enrolment in the study: Assessment of Socio-clinical profile, quality of life, Severity of side effects and Anxiety  
O2: Post-test on the day of first follow up chemotherapy cycle after enrolment: Assessment of quality of life, Severity of the chemotherapy related side effects and Anxiety  
O3: Post-test before on the day of second follow up chemotherapy cycle after enrolment: Assessment of quality of life, Severity of the chemotherapy related side effects and Anxiety
A structured 10-item questionnaire is developed by the researcher for assessment of socio-demographic variables which include Age, Gender, marital status, type of family, Cohabiting with, History of any substance abuse, educational status, occupation status, monthly income, socio-economic status (SES). SES will be measured using Modified Kuppuswamy Socioeconomic Status Scale which is one of the widely used scales for measuring socioeconomic status originally developed in 1976. It takes education status and occupation of the head of the family and total monthly family income into account. It is available on public domain.

An eight-item structured questionnaire developed by the researcher was used to elicit information on clinical variables including diagnosis, stage/grading of cancer, duration of illness, current chemotherapy cycle, last chemotherapy cycle received, treatment regimen, previous treatment of cancer, presence of comorbidity, any medications used, family history of chemotherapy received, vital signs, and biochemical profile.

Quality of life of GI cancer patients will be assessed using Functional Assessment of Cancer Therapy - General (FACT-G). FACT-G is a patient reported outcome measure five-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). It is comprised of four subscales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). Scores are calculated for each domain and in total as well where higher subscale and total scores indicate better QoL. The tool is available in both English and Hindi languages.

The chemotherapy related side effects including fatigue, anorexia, nausea, vomiting, diarrhea, mocositis, fever, abdominal pain, Palmar-Plantar erythrodysesthesia (hand-foot syndrome) and Biochemical parameters (Bilirubin, AST, ALT, ALP, GGT, INR, albumin and Creatinine) among GI cancer patients will be assessed by using Common Terminology Criteria for Adverse Events (CTCAE) Version-5.

The rigor of the qualitative data: The rigor of the qualitative data will be established using various strategies as described in table 2. The anxiety scores are then categorised into four severity levels as normal (0-7), mild (8-9), moderate (10-14), Severe (15-19) and Extremely Severe (20 and above). Translated versions of the tool are available in English and Hindi as well.

**Interview guide:** A semi structured interview guide is developed by the researcher to collect data for qualitative phase of the study as shown in table 2.

I. What problems did you face in performing activities of daily living after being diagnosed with Cancer?

II. What are the physical symptoms you experience?

III. How do you feel about caring yourself after being diagnosed with cancer?

IV. How is your relationship between you and your family members, relatives and with other people in your community?

V. What are the problems you have faced in establishing or maintaining the relationships with others after being diagnosed with cancer?

VI. How do you feel after the participating in the Nurse led tele-health Oncology clinic?

**Information Sheets:** The researcher developed an Investigator Log Book and Patient Diary to document data by the researcher and the patients regarding practicing of Progressive muscle relaxation therapy till the patient come for the follow up.

**Validity and Reliability of the tools:** The content validity of the tools was established by nine experts in the fields of medical surgical Nursing, Gastroenterology and Oncology. The reliability testing was performed using Cronbach’s alpha for internal consistency reliability for FACT-G, CTCAE version-5 and DASS whereas Inter-rater reliability was employed to assess the reliability of Checklist on skill of performing PMRT. All the tools were found to have adequate validity (CVI > 0.9) and reliability (r>0.8).

**Language validity:** All the tools have been validated by the experts in English and Hindi languages where in the tools were translated from English to Hindi language and vice-versa.

**Rigor of the qualitative data:** The rigor of the qualitative data will be established using various strategies as described in table 2.

**Data analysis:** Both descriptive and inferential statistical analysis will be carried out using the SPSS, version 29 and STATA (version 18). The data will be checked for normality and appropriate tests parametric or nonparametric will be used. The statistical significance will be fixed as conventional value of 0.05 (two-tailed). The continuous data will be presented as mean and standard deviation whereas categorical data will be presented as frequencies with percentages.
Table 2: Key strategies to be adapted to establish rigor of the qualitative data

<table>
<thead>
<tr>
<th>Rigor Criteria</th>
<th>Original Strategies</th>
<th>Planned Strategies to be applied to achieve rigor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Credibility</td>
<td>Prolonged and varied engagement with each setting</td>
<td>Interviewers will spend an average of 2–4 weeks to engage with participants.</td>
</tr>
<tr>
<td></td>
<td>Interviewing process and techniques</td>
<td>Interview protocol will be tested using 1–2 pilot interviews.</td>
</tr>
<tr>
<td></td>
<td>Establishing investigators’ authority</td>
<td>The investigators have the required knowledge and research skills to perform her roles.</td>
</tr>
<tr>
<td></td>
<td>Collection of referential adequacy materials</td>
<td>Interviewer will keep all the field notes safe for analysis and storage.</td>
</tr>
<tr>
<td></td>
<td>Peer debriefing</td>
<td>The investigator will have regular debriefing sessions with key members.</td>
</tr>
<tr>
<td>Dependability</td>
<td>Rich description of the study methods</td>
<td>The investigator will prepare detailed drafts of the study protocol throughout the study.</td>
</tr>
<tr>
<td></td>
<td>Establishing an audit trail</td>
<td>A detailed track record of the data collection process will be developed.</td>
</tr>
<tr>
<td>Confirmability</td>
<td>Reflexivity</td>
<td>We will examine own beliefs, judgments and practices that may influence the results and keep them aside. Also, a monthly investigator meeting will be kept to discuss the same.</td>
</tr>
<tr>
<td></td>
<td>Triangulation</td>
<td>We will apply triangulation techniques using both quantitative and qualitative approaches.</td>
</tr>
<tr>
<td>Transferability</td>
<td>Purposeful sampling to form a nominated sample</td>
<td>Extreme case sampling will be employed.</td>
</tr>
<tr>
<td></td>
<td>Data saturation</td>
<td>We will quantify operational and theoretical data saturation.</td>
</tr>
</tbody>
</table>

Data analysis: Both descriptive and inferential statistical analysis will be carried out using the SPSS, version 29 and STATA (version 18). The data will be checked for normality and appropriate tests parametric or nonparametric will be used. The statistical significance will be fixed as conventional value of 0.05 (two-tailed). The continuous data will be presented as mean and standard deviation whereas categorical data will be presented as frequencies with percentages.

Both the groups will be compared in terms of variables related to socio-demographic & clinical profile, quality of life, anxiety and severity of side effects to establish homogeneity among the groups at baseline. Wherever applicable Fisher’s exact or Chi square will be used to compare the categorical data whereas independent t test will be computed for continuous data. Any differences found will then be statistically adjusted.

To evaluate the effectiveness of the intervention, pretest total as well as subscale scores of Quality of life and anxiety will be compared with the respective post-test 1 and 2 scores using Repeated Measure ANOVA. To compare the severity of chemotherapy related side effects, chi square will be computed to compare frequency distribution at pretest and post-tests.

Logistic regression will be performed to describe the relationship between severity of side effect, anxiety and quality of life. Correlation between physical, social, emotional and functional wellbeing will be analysed using Karl Pearson correlation coefficient method. Association between total quality of life gain scores, gain scores of each QoL subscales and anxiety reduction score with socio-demographic and clinical variables will be analyzed using one way analysis of variance F-test and student independent t-test.

Simple bar diagram, Multiple bar diagram, simple bar with 2 standard Error bar, Box-plot and Scatter diagram with regression estimate will be used to represent the data.

Qualitative data analysis works with text-based unstructured data which will be available in the form of transcripts of audio-recorded interviews, field notes. Narrative analysis will be utilised to analyse the qualitative data which include five steps: organization and preparation of the data, obtaining a general sense of the information, coding process, categories or themes, and interpretation of the data.

The findings of the quantitative and qualitative phases will be integrated to find any commonalities.

Strengths and Limitations

The study utilises a mixed method approach which will help in establishing the generalizability of the study findings. The intervention developed by the researcher is validated by experts in the field. All the tools used are standardised tools.

One of the major limitations of the study is that the intervention developed is only for those GI cancer patients who are techno friendly.

Dissemination and Expected Outcomes of Study

The findings of the study will be presented at national and international conferences and published in
peer-reviewed journals. The study will help in the development of an Evidence Based Comprehensive Home-based Nursing intervention for GI cancer patients in the form of Nurse-led Tele-health Oncology Clinic which may be helpful in relieving severity of side effects of chemotherapy and anxiety and, hence improving the quality of life among GI cancer patients.

Additionally, a Nurse-led telehealth oncology clinic for GI cancer patients could have several significant implications as it leads to an increased access to care and convenience as telehealth eliminates geographical barriers, allowing patients in remote or underserved areas to access specialized oncology care and consultations bypassing the need of travel and associated expenses. It enhances the continuity of care, facilitates early intervention and empowers patients by providing them with greater control over their healthcare.

Through such clinics, Nurses can provide valuable emotional support and counselling to GI cancer patients and their families, helping them cope with the psychological and emotional challenges associated with cancer diagnosis and treatment.

Overall, a Nurse-led telehealth oncology clinic for GI cancer patients has the potential to revolutionize cancer care delivery by improving access, convenience, continuity, and patient outcomes while also reducing costs and enhancing patient satisfaction.

REFERENCES


